New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 28, 2013
08:38 EDTXNPT, BIIBXenoPort has positive readthroughs from clean Biogen label, says Wells Fargo
Wells Fargo believes that the benign FDA label for Biogen's (BIIB) Tecfidera indicates that regulators will have a favorable view of XenoPort's (XNPT) '829 treatment. The firm thinks that the label gives Biogen a better chance of maintaining exclusivity on its drug through 2028, possibly reducing the level of differentiation that XenoPort will need to demonstrate for '829. The firm maintains an Outperform rating on Xenoport.
News For XNPT;BIIB From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
August 31, 2015
19:26 EDTBIIBBiogen initiated with a Strong Buy at Raymond James
Target $400.
05:59 EDTBIIBStocks with implied volatility below IV index mean; BIIB TEVA
Stocks with implied volatility below IV index mean; Biogen (BIIB) 37, Teva (TEVA) 31 according to iVolatility.
August 28, 2015
09:15 EDTBIIBBiogen participates in a conference call with Barclays
Subscribe for More Information
06:01 EDTBIIBStocks with implied volatility below IV index mean; BIIB TEVA
Stocks with implied volatility below IV index mean; Biogen (BIIB) 38, Teva (TEVA) 31 according to iVolatility.
August 27, 2015
07:16 EDTBIIBApplied Genetic announces achievement of XLRS patient enrollement milestone
Subscribe for More Information
August 25, 2015
16:43 EDTBIIBOn The Fly: Top stock stories for Tuesday
Subscribe for More Information
09:03 EDTBIIBAcorda has major overhang removed by IPR denials, says Leerink
Subscribe for More Information
August 21, 2015
09:38 EDTBIIBUBS global healthcare analysts hold an analyst/industry conference call
Subscribe for More Information
August 20, 2015
16:24 EDTBIIBBiogen reports 8.1% passive stake in Applied Genetic
Subscribe for More Information
August 19, 2015
17:46 EDTBIIBApplied Genetic says Biogen collaboration effective, equity investment closed
Subscribe for More Information
August 18, 2015
08:21 EDTBIIBBiogen long-term outlook still positive, says RBC Capital
Subscribe for More Information
07:05 EDTBIIBBiogen, ALS Association, Columbia collaborate to drive understanding of ALS
Biogen, the ALS Association and Columbia University Medical Center announced a new collaboration to better understand the differences and commonalities in the ALS disease process and how genes influence the clinical features of the disease. The project, "Genomic Translation for ALS Clinical care", will involve a combination of next generation genetic sequencing and detailed clinical phenotyping in 1500 people with ALS. The goal of the project is to provide a basis for the development of precision medicine, or more individually tailored therapies for ALS. "We want to bring genomics right to the point of care in ALS where instead of focusing on retrospective DNA samples with limited clinical information, we focus on patients who are under active clinical management," said ALS Association Chief Scientist Lucie Bruijn, Ph.D., M.B.A. "By focusing on patients seen by participating ALS clinics, this project will allow investigators to ask how different genetic causes of ALS translate into different clinical consequences."

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use